Champions Oncology Earnings Estimate
| CSBR Stock | USD 9.22 0.01 0.11% |
Champions Oncology Revenue Breakdown by Earning Segment
By analyzing Champions Oncology's earnings estimates, investors can diagnose different trends across Champions Oncology's analyst sentiment over time as well as compare current estimates against different timeframes. At this time, Champions Oncology's Gross Profit is relatively stable compared to the past year. As of 03/17/2025, Gross Profit Margin is likely to grow to 0.53, while Pretax Profit Margin is likely to drop (0.18).
Champions |
Champions Oncology Earnings Estimation Breakdown
The calculation of Champions Oncology's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Champions Oncology is estimated to be 0.075 with the future projection ranging from a low of 0.075 to a high of 0.075. Please be aware that this consensus of annual earnings estimates for Champions Oncology is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.07 Lowest | Expected EPS | 0.07 Highest |
Champions Oncology Earnings Projection Consensus
Suppose the current estimates of Champions Oncology's value are higher than the current market price of the Champions Oncology stock. In this case, investors may conclude that Champions Oncology is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Champions Oncology's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of April 2025 | Current EPS (TTM) | |
| 1 | 27.57% | 0.33 | 0.075 | 0.45 |
Champions Oncology Earnings per Share Projection vs Actual
Actual Earning per Share of Champions Oncology refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Champions Oncology predict the company's earnings will be in the future. The higher the earnings per share of Champions Oncology, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Champions Oncology Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Champions Oncology, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Champions Oncology should always be considered in relation to other companies to make a more educated investment decision.Champions Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Champions Oncology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-03-10 | 2025-01-31 | -0.01 | 0.33 | 0.34 | 3400 | ||
2024-12-10 | 2024-10-31 | 0.01 | 0.05 | 0.04 | 400 | ||
2024-09-11 | 2024-07-31 | -0.03 | 0.11 | 0.14 | 466 | ||
2024-07-18 | 2024-04-30 | -0.16 | 0.01 | 0.17 | 106 | ||
2024-03-12 | 2024-01-31 | -0.06 | -0.16 | -0.1 | 166 | ||
2023-12-12 | 2023-10-31 | -0.17 | -0.15 | 0.02 | 11 | ||
2023-09-13 | 2023-07-31 | -0.1 | -0.19 | -0.09 | 90 | ||
2023-07-24 | 2023-04-30 | -0.12 | -0.19 | -0.07 | 58 | ||
2023-03-15 | 2023-01-31 | -0.04 | -0.18 | -0.14 | 350 | ||
2022-12-13 | 2022-10-31 | -0.01 | -0.0012 | 0.0088 | 88 | ||
2022-09-08 | 2022-07-31 | 0.01 | -0.02 | -0.03 | 300 | ||
2022-07-21 | 2022-04-30 | 0.03 | -0.03 | -0.06 | 200 | ||
2022-03-15 | 2022-01-31 | 0.03 | 0.05 | 0.02 | 66 | ||
2021-12-13 | 2021-10-31 | 0.01 | 0.02 | 0.01 | 100 | ||
2021-09-13 | 2021-07-31 | 0.01 | -0.01 | -0.02 | 200 | ||
2021-03-11 | 2021-01-31 | 0.01 | 0.05 | 0.04 | 400 | ||
2020-12-14 | 2020-10-31 | 0.0067 | 1.0E-4 | -0.0066 | 98 | ||
2020-09-14 | 2020-07-31 | 0.02 | 0.01 | -0.01 | 50 | ||
2020-07-27 | 2020-04-30 | 0.02 | -0.14 | -0.16 | 800 | ||
2020-03-12 | 2020-01-31 | 0.03 | 0.03 | 0.0 | 0 | ||
2019-12-16 | 2019-10-31 | 0.01 | 0.02 | 0.01 | 100 | ||
2019-09-16 | 2019-07-31 | 0.04 | -0.05 | -0.09 | 225 | ||
2019-07-15 | 2019-04-30 | 0.03 | -0.01 | -0.04 | 133 | ||
2019-03-18 | 2019-01-31 | 0.03 | 0.01 | -0.02 | 66 | ||
2018-12-17 | 2018-10-31 | 0.04 | 0.03 | -0.01 | 25 | ||
2018-09-13 | 2018-07-31 | 0.01 | 0.05 | 0.04 | 400 | ||
2018-07-26 | 2018-04-30 | -0.04 | -0.04 | 0.0 | 0 |
About Champions Oncology Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Champions Oncology earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Champions Oncology estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Champions Oncology fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -76.1 M | -72.3 M | |
| Retained Earnings Total Equity | -69.6 M | -73.1 M | |
| Earnings Yield | (0.11) | (0.13) | |
| Price Earnings Ratio | (8.13) | (7.72) | |
| Price Earnings To Growth Ratio | (0.27) | (0.26) |
Pair Trading with Champions Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Champions Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Champions Oncology will appreciate offsetting losses from the drop in the long position's value.Moving together with Champions Stock
| 0.73 | VRNA | Verona Pharma PLC Downward Rally | PairCorr |
Moving against Champions Stock
| 0.82 | ELUT | Elutia Inc | PairCorr |
| 0.72 | ESPR | Esperion Therapeutics | PairCorr |
| 0.64 | VTYX | Ventyx Biosciences | PairCorr |
| 0.6 | ELVN | Enliven Therapeutics | PairCorr |
| 0.58 | EWTX | Edgewise Therapeutics | PairCorr |
The ability to find closely correlated positions to Champions Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Champions Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Champions Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Champions Oncology to buy it.
The correlation of Champions Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Champions Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Champions Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Champions Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Champions Stock Analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.